• Monday, Jan 24, 2022
  • Last Update : 03:32 am

AstraZeneca/Oxford Covid-19 vaccine approved for use in UK

  • Published at 05:06 pm December 30th, 2020
covid-19 vaccine
Representational image Bigstock

The Oxford vaccine is cheaper to produce, and easier to store and transport compared to the Pfizer-BioNTech vaccine

Britain on Wednesday became the first country in the world to approve AstraZeneca and Oxford University's low-cost Covid-19 vaccine, raising hopes it will help tackle rising cases and ease pressure on creaking health services.

The independent Medicines and Healthcare products and Regulatory Agency (MHRA) said the vaccine "met its strict standards of safety, quality and effectiveness", and a roll-out was set for January 4.

Prime Minister Boris Johnson, who spent several days in intensive care with Covid-19 earlier this year, called it "truly fantastic news" and "a triumph for British science".

"We will now move to vaccinate as many people as quickly as possible," he tweeted.

Britain has already approved the Pfizer/BioNTech vaccine for general use, and some 800,000 people have received a first dose in the country's biggest ever vaccination drive.

But as daily Covid-19 infection rates hit record highs, the government is pinning its hopes on the Oxford/AstraZeneca jab, which is cheaper to produce, and easier to store and transport.

Unlike the Pfizer-BioNTech vaccine, it does not require ultra-low freezing temperatures and can use normal refrigerated supply chains, making it a more attractive proposition globally.

The partners, who have billed it as a "vaccine for the world", have also promised to provide it not-for-profit to developing nations, and hope to make up to three billion doses in 2021.

'Way out'

Britain is struggling with another surge in the virus, with a record 53,135 daily cases reported on Tuesday, heaping fresh pressure on health services during their busiest winter months.

More than 71,000 people testing positive for the disease have now died — one of the worst tolls in the world.

But doctors say many frontline healthcare workers have been struck down with a new, potentially more contagious variant of the virus, which is thought to be behind the surge.

More than 24 million people, or 43% of England alone, are already living under strict stay-at-home measures, with bars, restaurants, pubs and other entertainment closed.

Also read - Where are we in the Covid-19 vaccine race?

The government is under pressure to follow other European countries and introduce even tougher restrictions, including delaying the return to school next week.

Health Secretary Matt Hancock is due to update parliament on Wednesday about whether to tighten the screw further.

But he said approval of the new vaccine was a "way out of the pandemic".

"Now we need to hold our nerve while we get through this together," he added.

Britain has ordered 100 million doses and the Department of Health expects four million doses to be ready by the end of the year, and 40 million by the end of March.

AstraZeneca Chief Executive Officer Pascal Soriot called the approval "an important day for millions of people in the UK".

"It's exactly what we need right now," Andrew Hayward, professor of infectious diseases epidemiology at University College London, told BBC television.

A "step change" in transmissibility has created "a race between us and the virus, and we need to slow the virus down as much as we can whilst we get as many people vaccinated as possible", he added.


The Oxford/AstraZeneca vaccine is based on a weakened version of a common cold virus (adenovirus) in chimpanzees which has been genetically changed to stop Covid-19 replicating in humans.

It delivers genetic cargo into cells, giving them instructions how to fight SARS-CoV-2.

The vaccine costs about £2.50 ($3.40, 2.75 euros) per dose — a fraction of the price of the Moderna and Pfizer/BioNTech drugs — which Hancock said provided hope for the rest of the world.

"This vaccine will be made available to some of the poorest regions of the world at a low cost, helping protect countless people from this awful disease," he added.

On Sunday, Soriot said the vaccine provides "100% protection" against severe Covid-19 disease requiring hospitalization.

He predicted trials would show his firm had achieved a vaccine efficacy equal to Pfizer/BioNTech at 95% and Moderna at 94.5%.

Earlier trials had shown varying outcomes in the AstraZeneca shot's efficacy.

Initial large-scale trials in which volunteers in the UK and Brazil were given two full doses showed 62% effectiveness.

For volunteers who received a half-dose first and then a full dose one month later, however, the vaccine was found to have 90% efficacy.

The values were averaged to give the 70% figure reported by the developers in an interim study.

Facebook 88
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail